Health Condition 1: K279- Peptic ulcer, site unspecified, unspecified as acute or chronic, without hemorrhage or perforation
Conditions
Interventions
Intervention1: NIL: NIL
Sponsors
Sun Pharmaceutical Industries Ltd
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients aged >=18 years 2. Patients on PPI therapy for APD along with comorbidities which include endocrinological, neurological, gynaecological, cardiovascular, chronic infectious diseases, orthopedics and renal comorbidities 3. Patients with at least two visits to the clinic after the baseline visit will be included
Exclusion criteria
Exclusion criteria: 1. Incomplete records of the patients (i.e., records not fulfilling the abovementioned inclusion criteria) will be excluded
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To analyze the drug utilization pattern of PPIs along with clinical profile of APD patients with co-morbiditiesTimepoint: At baseline visit only | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Assessment of patient adherence 2. Prescription patterns of pantoprazole 3. Subgroup analysis of patients taking high dose of PPIsTimepoint: 1. The first outcome will be assessed at the end of the study, i.e., 12 months from the baseline 2. Second and Third outcomes will be assessed at the baseline visit only | — |
Countries
India
Contacts
Public ContactDr Srivani Palukuri
THB c/o Sekhmet Technologies Pvt Ltd.
Outcome results
None listed